ClinicalTrials.gg
RecruitingNCT05675930Updated Nov 2, 2026

A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant

A Phase 2 interventional study of Photobiomodulation Therapy and Placebo sham device in Graft-Versus-Host Disease, GVHD and Undefined, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 9 sites in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 454 studies in Graft vs Host Disease with a site in United States — 49 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Planned enrollment
127th of 389
44 · median 30
Started
2022
with 12 others
Phase 2
164 of 454
15 open now
Primary completion
2026-12
later than 15 of 66 live
Registered
419th of 454
by date
Lead sponsor
9 of 454
Memorial Sloan Kettering Cancer Center

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 127th largest by planned enrollment of the 389 interventional ones that give a count, is one of 13 that started in 2022, is one of 164 in phase 2, reaches primary completion later than 15 of the 66 other live ones, and was the 419th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

49 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.

03

Conditions studied

  • Graft-Versus-Host Disease
  • GVHD
  • Undefined

Browse trials for

Keywords

  • Graft-Versus-Host Disease
  • GVHD
  • Chronic Graft Versus Host Disease Oral
  • PhotobiomoduLatIon
  • Memorial Sloan Kettering Cancer Center
  • 22-271
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Allo-HCT recipients
  • Age ≥ 4 years-old
  • Oral cGvHD with NIH-modified OMRS score ≥ 3 who have failed ≥ 1 , including topical ..
  • No change in systemic therapy (type or intensity level) within 2 weeks prior to enrollment.
  • If a patient is currently using another oral topical treatment for mouth lesions/symptoms, patient must be stable on this treatment for ≥2 weeks prior to study enrollment. Patient may continue same topical dose/frequency during the study period.

Exclusion criteria

Exclusion Criteria:

  • Presence of an active uncontrolled infection. Subjects with a controlled infection receiving definitive therapy for 48 hours prior to enrollment are eligible.
  • Personal history of mucosal head and neck cancer in the past 5 years.
  • Pregnant or breastfeeding.
  • The subject or guardian is unable to give or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests.
  • Any serious medical or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
44 participants (estimated)

Study arms

  • Active comparator
    Adult and pediatric patients who received an allogeneic stem cell transplant (allo-HCT)

    Participants are Allo-HCT recipients

    Device: Photobiomodulation Therapy

  • Placebo comparator
    Adult and pediatric patients who received a placebo treatment

    Participants are Allo-HCT recipients

    Other: Placebo sham device

Interventions

  • DevicePhotobiomodulation Therapy

    Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the treatment arm will be treated with oral photobiomodulation/PBM (via Thor LX2.3 system device) for 28 days

    Also known as: PBM Therapy, Thor LX2.3 system device

  • OtherPlacebo sham device

    Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the placebo arm will be treated with a placebo sham device (via Thor LX2.3 sham device setting) for 28 days

    Also known as: Thor LX2.3 sham device setting

06

What researchers measure

Primary outcomes

  1. Response rate of participants

    To assess the primary objective, we will compare the treatment response rates, defined as the the proportion of oral GvHD allo-HCT patients who achieve a CR or a PR at Day 28, for the PBM and Placebo arms. The treatment response rate will be calculated within each study arm for all patients who completed at least one PBM or placebo treatment.

    Time frame: 28 days

07

Study locations

9 of 9 sites recruiting
  • National Institute of Health (Data Collection AND Specimen Analysis)
    Bethesda, Maryland 20892, United States
    Recruiting
  • Memorial Sloan Kettering at Basking Ridge (Consent only)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Alina Markova, MD · Contact646-608-2342
  • Memorial Sloan Kettering Monmouth (Consent only)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Alina Markova, MD · Contact646-608-2342
  • Memorial Sloan Kettering Cancer Center @ Bergen (Consent only)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Alina K Markova, MD · Contact646-608-2342
  • Memorial Sloan Kettering Cancer Center @ Commack (Consent only)
    Commack, New York 11725, United States
    Recruiting
    • Alina K Markova, MD · Contact646-608-2342
  • Memorial Sloan Kettering Westchester (Consent only)
    Harrison, New York 10604, United States
    Recruiting
    • Alina Markova, MD · Contact646-608-2342
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Alina Markova, MD · Contact646-608-2342
  • Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)
    Uniondale, New York 11553, United States
    Recruiting
    • Alina K Markova, MD, PhD · Contact646-608-2342
  • University of Pittsburgh Medical Center (Data Collection Only)
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

Of 86 non-industry phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 116. This study's planned 48 months is below that.

Counting every sponsor, half of 103 studies reached it within 52 months; a quarter within 29 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2022
First posted
Jan 9, 2023
StartActual
Dec 22, 2022
Primary completionEst.
Dec 22, 2026
CompletionEst.
Dec 22, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05675930
Responsible party
Sponsor
First posted
Jan 9, 2023
Start date
Dec 22, 2022
Primary completion
Dec 22, 2026 (estimated)
Completion
Dec 22, 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Alina Markova, MD
Contact
markovaa@mskcc.org
6466082342
Doris Ponce, MD
Contact
ponced@mskcc.org
646-608-3739
Alina Markova, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion